Alternate cyclin D1 mRNA splicing modulates P27\u3csup\u3eKlP1\u3c/sup\u3e binding and cell migration by Li, Zhiping et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Cancer Biology Faculty Papers Department of Cancer Biology
January 2008
Alternate cyclin D1 mRNA splicing modulates
P27KlP1 binding and cell migration
Zhiping Li
Thomas Jefferson University
Chenguang Wang
Thomas Jefferson University
Xuanmao Jiao
Thomas Jefferson University
Sanjay Katiyar
Thomas Jefferson University
Mathew C. Casimiro
Thomas Jefferson University
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/cbfp
Part of the Amino Acids, Peptides, and Proteins Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Cancer Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Li, Zhiping; Wang, Chenguang; Jiao, Xuanmao; Katiyar, Sanjay; Casimiro, Mathew C.; Prendergast,
George C.; Powell, Michael J.; and Pestell, Richard G., "Alternate cyclin D1 mRNA splicing
modulates P27KlP1 binding and cell migration" (2008). Department of Cancer Biology Faculty Papers.
Paper 12.
https://jdc.jefferson.edu/cbfp/12
Authors
Zhiping Li, Chenguang Wang, Xuanmao Jiao, Sanjay Katiyar, Mathew C. Casimiro, George C. Prendergast,
Michael J. Powell, and Richard G. Pestell
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/cbfp/12
This is the author’s final version of an article published in the Journal of Biological Chemistry.   
The published version is available at http://www.jbc.org/cgi/doi/10.1074/jbc.M706992200. 
Copyright 2008 by The American Society for Biochemistry and Molecular Biology, Inc.  
 
ALTERNATE CYCLIN D1 mRNA SPLICING MODULATES P27
KIP1
 BINDING AND CELL 
MIGRATION  
 
Zhiping Li
1
, Chenguang Wang
1*
, Xuanmao Jiao
1
, Sanjay Katiyar1, Mathew C. Casimiro1, 
George C. Prendergast
2
, Michael J. Powell
1
, and Richard G. Pestell
1* 
 
1
Kimmel Cancer Center, Departments of Cancer Biology and Medical Oncology, Thomas 
Jefferson  
University, Philadelphia, PA. 19107. USA and  
2 
Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA. 19096. 
USA  
 
*Corresponding Authors: Richard G. Pestell, Chenguang Wang.  
Departments of Cancer Biology and Medical Oncology 
Kimmel Cancer Center 
Thomas Jefferson University 
233 South 10th Street 
Bluemle Life Sciences Building, Room 1050 
Philadelphia, PA  19107.  
Tel: 215-503-5649 
Fax: 215-923-9334 
Email: Richard.Pestell@jefferson.edu, chenguang.wang@jefferson.edu  
For reprints: aja.jackson@jefferson.edu  
 
 
ABSTRACT 
 
Cyclin D1 is an important cell cycle regulator but in cancer its overexpression also 
increases cellular migration mediated by p27KlP1 stabilization and RhoA inhibition. 
Recently, a common polymorphism at the exon 4-intron 4 boundary of the human cyclin 
D1 gene within a splice donor region was associated with an altered risk of developing 
cancer. Altered RNA splicing caused by this polymorphism gives rise to a variant cyclin 
D1 isoform termed cyclin D1b, which has the same N-terminus as the canonical cyclin 
D1a isoform but a distinct C-terminus. In this study we show that these different 
isoforms have unique properties with regard to the cellular migration function of cyclin 
D1. Whereas they displayed little difference in transcriptional co-repression assays on 
idealized reporter genes, microarray cDNA expression analysis revealed differential 
regulation of genes including those that influence cellular migration. Additionally, while 
cyclin D1a stabilized p27
KIP1
 and inhibited RhoA-induced ROCK kinase activity, 
promoting cellular migration, cyclin D1b failed to stabilize p27
KIP1
 or inhibit ROCK kinase 
activity and had no effect on migration. Our findings argue that alternate splicing is an 
important determinant of the function of cyclin D1 in cellular migration.  
  
The cyclin D1 gene was initially cloned as a breakpoint rearrangement in 
parathyroid adenoma (1). Subsequent studies confirmed increased cyclin D1 
abundance in a variety of tumors including breast and gastrointestinal tumors (2). 
Molecular analysis demonstrated the cyclin D1 gene encodes the regulatory subunit of 
a holoenzyme that phosphorylates and inactivates the retinoblastoma protein, pRb. 
Immunoneutralizing and antisense experiments revealed the requirement for cyclin D1 
in progression through the early G1 phase of the cell cycle (reviewed in (2)). In addition 
to binding Cdks, cyclin D1 associates with several different intracellular proteins 
including the estrogen receptor (ERα), PPARγ, P/CAF (p300/CBP associated factor) 
(3,4) and the cyclin D1 myb-like binding protein (DMP1) (5-8). Cyclin D1 binds to ERα in 
breast cancer cells and overcomes the BRCA1-mediated repression of ERα activity 
(9,10). Homozygous deletion of the cyclin D1 gene results in mice with failure of 
terminal alveolar breast development during pregnancy, increased basal and UV-
induced apoptosis, retinal apoptosis, defective angiogenesis, hepatic steatosis, and 
defective cellular migration (4,11-14).  
 
Previous epidemiological and clinical observations have demonstrated a 
correlation between cyclin D1 overexpression and cellular metastases (15). Molecular 
genetic analysis subsequently revealed a key role for cyclin D1 in cellular adhesion and 
migration (14). In particular, cyclin D1-deficient cells showed enhanced cellular 
adhesion and reduced migration into a wound, and genetic complementation 
experiments established a requirement for the CDK-binding but not the pRB-binding 
domain of cyclin D1 to rescue the cell migratory defect (16,17). Together, these studies 
demonstrated a key role for cyclin D1 in cell migration, including bone marrow-derived 
macrophages, fibroblasts, and mammary epithelial cells (14,16,17).  
 
Recently, a common polymorphism identified in the human cyclin D1 gene was 
found to be associated with an increased risk of cancer development (18-22). This 
polymorphism (A870G), located at the splice donor region at the exon 4-intron 4 
boundary, modulates the efficiency of alternate splicing between exon 4 and  
5. As a result of the altered splicing which occurs, the coding region downstream is 
altered such that the amino acid sequence of the carboxyl-terminus of cyclin D1 is 
altered (18). Thus, the two isoforms of cyclin D1 produced, the canonical isoform 
termed cyclin D1a and the alternately spliced isoform termed cyclin D1b, are identical in 
their N-termini but distinct in their C-termini. Notably, clinical studies have associated 
this polymorphism with an increased risk of colon and rectal cancer, early-onset 
squamous cell carcinoma, head and neck cancer, and transitional cell carcinoma of the 
bladder (23). Elegant in vitro analyses have demonstrated that the cyclin D1a and D1b 
isoforms have similar half lives in cultured cells, however, the cyclin D1b isoform is 
primarily nuclear in subcellular localization and relatively more resistant to 
phosphorylation-dependent nuclear export (24). Cyclin D1a blocks cells at the G1 phase 
whereas cyclin D1b blocks cells at the G0 phase in some (23), but not all studies (25).  
Notably, while both isoforms encode regulatory subunits, cyclin D1b has a reduced 
capacity to phosphorylate pRb (25,26). Yet despite serving as a less effective 
component of this pRb kinase, cyclin D1b conveys a greater transforming capacity 
which enhances colony formation of NIH3T3 cells. Thus, the basis for the enhanced 
transforming ability of cyclin D1b has been unclear.  
 
The Cdk inhibitor p27
KIP1
 inhibits most cyclin/Cdk complexes, including cyclin 
E/Cdk2 and cyclin D/Cdk4 (27). In the majority of studies, reduced p27KIP1 in tumors 
correlates with a poorer prognosis (28-31).  p27KIP1 plays an important role in regulating 
cellular migration through regulating either Rac (32), Rho GTPase activity (16,33) or 
Stathmin function (34).  Mechanistic analyses presented here reveal that cyclin D1b 
evades binding to p27
KIP1
 which may explain the increased cell transforming activity of 
this isoform. Furthermore, cyclin D1b lacks the pro-migratory function of cyclin D1a, 
implicating the C-terminal region and alternate splicing as important determinants of this 
function.   
Experimental procedures 
Cell culture - Cyclin D1
+/+
 and cyclin D1
-/-
 primary mouse embryonic fibroblasts (MEFs) 
cultures were prepared as described previously (4) and passaged by the original 3T3 
protocol (35). Human kidney 293T and MCF-7 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing penicillin and streptomycin (100 mg of 
each/liter) and supplemented with 10% FBS.   
 
Retroviral production and infection - Retroviral production and infection of cyclin D1
-/-
3T3 cells were previously described (16). Fluorescence-activated cell sorting (FACS) 
(DakoCytomation MoFlo; Dako Denmark) sorted GFP+ cells were used for subsequent 
analysis.    
 
Immunofluorescence - Phalloidin, paxillin and tyrosine phosphorylated paxillin (pY118) 
staining were conducted as previously described (14,16). The samples were visualized 
on a Zeiss LSM 510 META Confocal Microscope with a 63× objective.  
 
Immunoprecipitations and Western blotting - Cyclin D1
-/-
 MEFs or 3T3 cells infected 
with GFP vector control or cyclin D1 wild type (D1a) or splice variant (D1b) were lysed 
in immunoprecipitation (IP) buffer (10 mM Tris-HCL at pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% IGEPAL CA630, 10% glycerol, 1 mM 
sodium orthovanadate and protease inhibitor cocktail (Boehringer Mannheim). For each 
IP, 1 ml lysate (1 mg protein) and 10 µl anti-FLAG M2-agarose affinity gel (Sigma, St. 
Louis, MO) were incubated overnight at 4oC. Immunoprecipitates were washed 5 times 
in IP buffer, and 20 µl of 2×sample buffer was added to the bead pellet. The 
immunoprecipitates, as well as 50 µg of proteins from the corresponding lysates were 
subjected to Western blotting as previously described (36). The following antibodies 
were used for Western blotting: mouse M2 anti-FLAG antibody, antivinculin antibody 
(Sigma, St. Louis, MO), and anti β-tubulin antibody, mouse anti-cyclin D1 antibody 
(DCS-6), rabbit polyclonal anti-p27KIP1 antibody (C-19), rabbit polyclonal antibody for 
Ser3 phospho-ADF/cofilin (Santa Cruz Biotechnology, Santa Cruz, CA).  
 
Time-lapse video -  For time-lapse observation of cell movement, cells were plated in 
12 well plates in DMEM with 10% FCS and HEPES. Cells were placed in a 
temperature- and CO2-controlled incubator to maintain the temperature at 37
o
C and 
CO2 at 5%. The cell movement videos were snapped at 5 minute intervals for 2 hours 
by using a Zeiss Axiovert 200M Inverted Microscope System. The cell movement 
velocity was determined by tracing several single cells at different time points using 
MetaMorph software.   
 
Mammalian two-hybrid and luciferase reporter gene assays - Mammalian two-
hybrid was performed by following the manufacturer’s instruction (Promega) and was 
described previously (17). Human p27KIP1, cyclin D1a or D1b cDNAs were cloned into 
pBIND vector and pACT vector to generate fusion proteins with the DNA binding 
domain of GAL4 (Gal4-p27Kip1, Gal4-D1a, Gal4-D1b) and the activation domain of VP16 
(VP16-p27KIP1, VP16-D1a, VP16-D1b), respectively. Gal4-PPARγ, Gal4-AR, and Gal4-
NRF1 were previously described (3,4,37). Gal4p27KIP1, VP16-cyclin D1, and pG5luc, 
which contains five Gal4 binding sites upstream of a minimal TATA box and the firefly 
luciferase gene (Promega) or Gal4-cyclin D1, VP16-p27KIP1 and pG5luc were 
cotransfected into MCF-7 cells with Superfect transfection reagent. Two days after 
transfection, the cells were lysed and luciferase activity quantitated as previously 
described (4). Luciferase activity was normalized for transfection efficiency using a β-
galactosidase reporter (CMVβ-gal) as an internal control.  
 
Northern blot and pulse chase analysis - Total RNA samples were prepared from 
cyclin D1
-/-
3T3 cells infected with cyclin D1a, D1b, or vector control with the Trizol 
reagent (Invitrogen). For Northern blot, 10 µg of RNA per sample was separated on 
0.9% formaldehyde-agarose gel, transferred, and hybridized by using Rapid-hyb Buffer 
(Amersham/GE Healthcare, Piscataway, NJ). Mouse p27KIP1 probe, mouse β-actin 
probe, and human cyclin D1 probe were labeled with [α32P]dCTP by using the Ready-
to-go kit (Amersham/GE Healthcare, Piscataway, NJ). Mouse p27KIP1 and mouse β-
actin probes were RTPCR products. 1 µg of total RNA from cyclin D1
-/-
MEFs infected 
with cyclin D1a was used for cDNA synthesis with the Superscript Reverse 
Transcriptase (Invitrogen). RT-PCR products were obtained with the following primers: 
p27
Kip1 
primers: forward: 5’CGTGAGAGTGTCTAACGGG-3’ and reverse: 5’-
CGAGTCAGGCATTTGGTCC-3’. β-actin primers: forward: 5’-
TGTTACCAACTGGGACGACA-3’ and reverse: 5’-AAGGAAGGCTGGAAAAGAGC-3’. 
The human cyclin D1 probe was the fragment between HindIII and NcoI from MSCV-
cyclin D1a-IRESGFP retroviral vector. The filters were exposed to X-ray films at –80
o
C. 
Pulse chase analysis was conducted as previously described (38).  
 Real-time RT-PCR - Total RNA samples from cyclin D1
-/-
cells transfected with MSCV-
IRESGFP, MSCV-cyclin D1a-IRES-GFP or MSCVcyclin D1b-IRES-GFP were subjected 
to DNase I (RQ1 DNase: Promega Corp, Madison, WI) treatment to remove 
contaminating DNA from RNA preparations followed by their re-purification using 
Qiagen RNAEasy RNA columns (Qiagen, Valencia, CA). Equal amounts of purified 
RNA samples were reverse transcribed using Iscript Reverse transcriptase kit (Bio-Rad, 
Hercules, CA) to form cDNA which was then subjected to SYBR Green based Real-
Time PCR relative quantification method for amplification of p27
KIP1
 transcripts using 
standard hot-start reaction mixes and conditions (39) in an ABI Prism 7900HT (Applied 
Biosystems, Foster City, CA). The primers used for amplification of p27KIP1 were: 
forward 5’ TCTCTTCGGCCCGGTCAAT 3’ and reverse 5’ 
GGGGCTTATGATTCTGAAAGTCG 3’. Amplification of 18S rRNA housekeeping gene 
transcript (primer ref (40)) was performed in every sample and the obtained Ct values 
for each sample were used for normalization of data for p27
KIP1 
expression in ABI Prism 
SDS 2.3 software. To calculate the fold change in p27
KIP1
 gene expression between 
various treatments Ct values obtained from amplification of p27
KIP1
 transcripts in MSCV-
IRES-GFP were used for calibration.  
 
Microarray analysis - Total RNA (5µg) was reverse transcribed using Superscript III 
First-Strand Synthesis System (Invitrogen) using a HPLC purified T7-dT24 primer 
(Sigma Genosys) which contains the T7 polymerase promoter sequence. The single 
stranded cDNA was converted to double stranded cDNA using DNA polymerase I 
(Promega) and purified by cDNA spin column purification using GeneChip Sample 
Cleanup Module (Affymetrix). The double stranded cDNA was used as a template to 
generate biotinylated cRNA using Bioarray HighYield RNA Transcription Labeling Kit 
(Enzo) and the labeled cRNA purified by GeneChip Sample Cleanup Module 
(Affymetrix). 15µg of cRNA was fractionated to produce fragments between 35–200 bp 
using 5x Fragmentation buffer provided in the Cleanup Module. The sample was 
hybridized to mouse 430 2.0 microarray (Affymetrix) representing approximately 39,000 
well-characterized mouse transcripts. The hybridization and washing steps were carried 
out in accordance with Affymetrix protocols for eukaryotic arrays. The arrays were 
scanned at 570nm with a confocal scanner from Affymetrix.  
 
Array data analysis - Analysis of the arrays was performed using R-statistics package 
and the limma library of the Bioconductor software package (37). Arrays were 
normalized using robust multiarray analysis (RMA), and P-value of  
0.05 was applied as criteria for statistically significant differentially expressed genes 
between Cyclin D1a or Cyclin D1b rescued 3T3 compared to GFP control. GO tree 
analysis of gene function analyzed by “Webgestalt” 
(http://bioinfo.vanderbilt.edu/webgestalt) (41) and affymetrix gene annotation.  
 
Results  
Genes associated with cell migration are preferentially regulated by cyclin 
D1a but not cyclin D1b. Cyclin D1a functions as a transcriptional coregulator in part by 
recruiting HDAC and controlling p300 HAT activity (2,42,43). For example, cyclin D1a 
inhibits PPARγ signaling and transactivation in vitro and in vivo (4,42). To compare the 
transcriptional repression function of cyclin D1b, we evaluated its effects on PPARγ 
activity using a heterologous reporter system in which PPARγ was linked to the Gal4-
DNA binding domain. Consistent with prior studies, cyclin D1a inhibited PPARγ activity 
while cyclin D1b also repressed PPARγ activity to a similar extent (Fig. 1A). Cyclin D1 
also inhibits mitochondrial biogenesis, in part by inhibiting the transcriptional activity of 
NRF1 (37). Herein, both cyclin D1a and cyclin D1b inhibited NRF1 activity (Fig. 1A).  
Consistent with recent studies (44), cyclin D1b repressed androgen receptor activity. To 
further compare the effects of the cyclin D1 isoforms on transcription, we performed a 
genome-wide analysis of how they affected gene expression in cyclin D1
-/-
mouse 
embryo fibroblast derived 3T3 cells. The cyclin D1
-/-
cells were transduced with specific 
retroviral vectors. Previous work has shown that cyclin D1 regulates the expression of 
genes involved in cellular migration in early passage MEFs (16). 3T3 cells transduced 
with retroviral vectors expressing each cyclin D1 isoform were processed for mRNA 
analysis. Similar levels of cyclin D1 isoform were expressed by each vector as 
determined by Western blotting (Fig. 2C, Fig. 3A). We found that 19 genes were 
regulated concordantly by both cyclin D1a and cyclin D1b (Fig. 1B). Distinct genes were 
regulated by cyclin D1a vs. cyclin D1b. Cyclin D1a expression altered the abundance of 
661 genes, of which 397 genes were induced and 264 genes repressed >1.3-fold, 
compared with vector control. Cyclin D1b regulated expression of 60 genes, 1/3 of 
which (19 genes) were regulated concordantly by cyclin D1a. Cyclin D1a regulated a 
distinct cluster of genes that function to promote cellular migration and invasion. These 
genes were not regulated by cyclin D1b (Supplemental Data 1, Table 1, For full details 
the GEO accession number obtained is GSE9161 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi 
?token=zfellwagiuaagfa&acc=GSE9161). Cyclin D1b regulated genes function in DNA-
dependent transcription and nucleosome assembly (Supplemental Data  2, Table 2).  
 
Cellular migration is promoted by cyclin D1a but not cyclin D1b. MEFs 
genetically deficient in cyclin D1 spread with a circumferential distribution of adherent 
focal contacts (16). Cyclin D1 promotes cellular migration of bone marrow 
macrophages, fibroblasts, mammary epithelial cells and vascular endothelial cells 
(14,16,45). To evaluate whether both cyclin D1 isoforms promote focal contact 
distribution and cellular migration, retroviral transduced cells co-expressing green 
fluorescence protein (GFP) via an internal ribosomal entry site (IRES) were sorted after 
transduction for analysis. Consistent with previous studies, cyclin D1
-/- 
 MEFs assumed 
a flattened spread morphology by phase contrast microscopy  (Supplemental Data 3). 
Cell contacts were monitored by confocal microscropy using antibodies specific for 
tyrosine-phosphorylated paxillin (Y118). Consistent with previous observations, cyclin 
D1
-/-
MEFs showed a peripheral distribution of focal contacts as revealed by tyrosine-
phosphorylated paxillin (Y118) (Fig. 2A). Cyclin D1a-expressing cells markedly reduced 
the peripheral distribution of tyrosine phosphorylated paxillin. In contrast, cyclin D1b 
failed to reverse this phenotype (Fig. 2A).  
 
To compare effects on cell migration, GFP positive cells were examined by 
phase contrast video microscopy. Previous studies have demonstrated that cyclin D1 
regulates F-actin organization and promotes migration through inhibition of the RhoA-
regulated ROCK kinase (16,17). Consistent with these studies, cyclin D1-/-MEFs 
expressing cyclin D1a appeared polarized (Fig. 2A) and phalloidin staining 
demonstrated a reduction in F-actin staining. In contrast, although similar protein levels 
were expressed in cyclin D1b-transduced cells, no alteration in cellular morphology was 
observed (Fig 2A). Cellular movement velocity was determined at regular 5 min 
intervals. As expected, velocity was enhanced by expression of cyclin D1a but not by 
the cyclin D1b isoform (Fig. 2B).   
 
Cyclin D1 enhances cellular migration by inhibiting ROCK kinase activity as 
evidenced by reduced phosphorylation of the actin-depolymerizing protein cofilin at 
serine 3 (Ser3) (17). In transduced cyclin D1-/-cells, cyclin D1a reduced ROCK activity 
as evidenced by a ~2-fold reduction in Ser3 phosphorylation of cofilin relative to vector-
only transduced control cells (Fig. 2C). Additionally, cyclin D1a induced p27KIP1 
abundance ~5-fold (Fig. 2C). In contrast, cyclin D1b did not significantly affect either 
Ser3cofilin phosphorylation or p27
KIP1
 abundance (Fig. 2C).  
 
p27
KIP1
 is stabilized by cyclin D1a but not cyclin D1b. Because of the strength of 
the evidence that p27
KIP1
 control is critical for cyclin D1a-mediated cellular migration 
(17), we further compared how cyclin D1b affected p27KIP1 to gain further insight into the 
basis for its differential effects on cellular migration. Replicate experiments with different 
cyclin D1
-/-
MEF preparations indicated that p27
KIP1
 levels were induced ~3-fold on 
average by cyclin D1a (Fig. 3A). In contrast, cyclin D1b transduction reduced p27KlP1  
abundance ~40%. This difference was unrelated to levels of isoform expression as 
similar levels of cyclin D1a and cyclin D1b were produced in cells as confirmed by 
Western blotting (Fig. 3A). p27KIP1 is regulated at multiple levels including transcription 
(46), translation (47) and post-translational (48). Because cyclin D1a acts as a 
transcriptional co-regulator we examined whether cyclin D1 regulated p27
KIP1
 mRNA 
abundance. However, neither isoform affected the steady-state levels of p27
KIP1 
mRNA 
as determined by Northern blot analysis or QT-PCR (Fig. 3B,C). We next examined 
whether the increased levels of p27
KIP1 
protein reflected an increase in protein stability. 
Cyclin D1
-/-
 MEFs were transduced with retroviral vectors encoding cyclin D1a or cyclin 
D1b and protein abundance determined after cycloheximide treatment. A representative 
example (Fig. 4A) and mean data of multiplicate experiments (Fig. 4B) are shown. In 
cells transduced by cyclin D1a, the relative abundance of p27
KIP1 
protein was increased 
~2.5 fold at each time point determined after protein synthesis inhibition by 
cycloheximide, compared to cyclin D1b (Fig. 4). Pulse chase analysis was conducted to 
determine the effect of the cyclin D1 isoforms on newly synthesized p27
KIP1 (Fig. 4C). 
Cyclin D1
-/-
3T3s were transduced with retroviral vectors encoding cyclin D1a or cyclin 
D1b. The rate of newly synthesized p27
KIP1
 was increased approximately 2-fold by 
cyclin D1a 1 hr after the initiation of the pulse chase, but was similar by 2 hrs. Together 
these results argue that cyclin D1a increases p27
KIP1 
levels through promoting 
stabilization of the protein when compared with the effects of cyclin D1b.   
 
Cyclin D1b displays reduced binding to p27
KIP1
. Previous studies have 
documented a physical interaction between p27
KIP1
 and cyclin D1a by 
immunoprecipitation and mammalian two-hybrid assays (17,49). We therefore 
compared the ability of cyclin D1b to interact with p27
KIP1
 in these assays. In a 
mammalian two hybrid system, we confirmed that cyclin D1a interacted with p27
KIP1 
and 
that point mutation of the cdk4-binding domain of cyclin D1a (D1KE) abrogated this 
interaction (Fig. 5B). By comparison, the cyclin D1b isoform exhibited a relative ~80%  
reduction in p27
KIP1
 interaction. As the cyclin D1a and cyclin D1b are similar for the 
amino acids encoded by exons 1-4 but differ in their carboxyl terminal amino acid 
structure (Fig. 5A), these studies implicated the cyclin D1a carboxyl terminus encoded 
by exon 5 in the interaction with p27
Kip1
. A carboxyl terminal deletion mutant of cyclin 
D1a residues encoding exon 5 (Cyclin D1N2) was therefore generated. This mutant of 
cyclin D1a was defective in p27
KIP1
 interaction in mammalian 2-hybrid (Fig. 5B). Similar 
results were obtained by a reciprocal analysis in which the p27
KIP1 
and cyclin D1 
polypeptides were swapped in as fusions to the Gal4 DNA-binding domain and VP16 
transactivation domain employed in this system (Fig. 5B, right hand panel). We 
confirmed these findings by an immunoprecipitation analysis conducted in retroviral 
vector-transduced cyclin D1
-/-
MEFs that were subjected to GFP-based cell sorting (Fig. 
5C). As before, similar levels of cyclin D1a and cyclin D1b were expressed as 
documented by Western blotting (Fig. 5C; Input). Immunoprecipitation using the amino-
terminal FLAG epitope included in the construct confirmed similar amounts of cyclin D1 
protein. Western analysis of the cyclin D1 immunoprecipitates identified p27
KIP1
 
associated with cyclin D1a. However, only ~1/10 of the amount of p27
KIP1 
present in 
these immunoprecipitates was present in a similar cyclin D1b immunprecipitate in 
replicate experiments (Fig. 5C). The role of the cyclin D1a carboxyl terminus in 
interaction with Cdk4 in mammalian 2-hybrid was next assessed. The cyclin D1b and 
cyclin D1N2 displayed an approximately 50% reduction in interaction compared with 
cyclin D1a (Fig. 5D).   
Discussion  
The present study extends the understanding of cyclin D1 splice variants (26) by 
demonstrating that the two distinct isoforms differ in their fundamental biological and 
biochemical properties. An unbiased genomic approach was used to identify genes 
regulated by cyclin D1a vs. cyclin D1b.  This type of study does not necessarily identify 
direct transcriptional targets but demonstrated approximately 1/3 or the genes regulated 
in response to cyclin D1b were also regulated by cyclin D1a.  The functions of genes 
regulated by cyclin D1b only include genes involved in DNA-dependent transcription 
and nucleosome assembly. Previous studies had characterized transcriptional 
repression function of cyclin D1a implicating a predicted helix-loophelix domain (4).  
This domain is conserved with cyclin D1b, and both cyclin D1a and cyclin D1b 
maintained repression function of the heterologous transcription factor domains for the 
AR, NRF1 and PPARγ.  
 
Cyclin D1a induces cellular polarity and migration, increasing cellular movement 
velocity. The molecular mechanism for these effects involves an inhibition of Rho 
signaling, as evidenced by a specific reduction in the phosphorylation of the actin 
severing protein cofilin at Ser3. In contrast, cyclin D1b failed to promote cellular 
polarization and cellular migration, failed to inhibit cofilin phosphorylation, and failed to 
stabilize p27
KIP1
. Associated with these defects, cyclin D1b was also defective in its 
ability to effectively interact with p27
KIP1
, as measured in mammalian two-hybrid assays 
and co-immunoprecipitations from mouse cells.  
 
Cyclin D1a increased the abundance of p27
KIP1 
by promoting the stability of this 
important cell regulator. The crystal structure of the amino-terminal 69 residues of the 
p27
KIP1
 inhibitory domain bound to phosphorylated cyclin A/Cdk2 contributed to the 
understanding that p27
KIP1 
contains separate binding sites for the cyclin and the kinase 
(50). One key mechanism governing p27KIP1 stability involves an SCF ubiquitin ligase 
(E3) complex which induces p27KIP1 ubiquitination and degradation by the ubiquitin-
proteosome system. An additional ubiquitin ligase, KPC (KIP1 ubiquitination-promoting 
complex) has been described.   The mechanisms by which cyclin D1a induce p27KIP1 
involves regulation of Skp2 expression, protection of p27
KIP1 
from degradation due to its 
association with the cyclin, and the induction of p27
KIP1 
phosphorylation at Ser10 (17).  
 
Cyclin D1a regulated expression of genes in 3T3 cells that are known to either 
inhibit adhesion and/or promote migration.  These findings in 3T3 cells are consistent 
with prior findings that cyclin D1a promotes migration in non-transformed cells including 
macrophages and mammary epithelial cells (14,16,17). The genes regulated by cyclin 
D1a include thrombospondin 1 (TSP-1), procollagen, type VIII, alpha 1 (Col8a1),  
junction plakoglobin (Jup), ras homolog gene family, member B (RhoB), and cadherin 2 
(Cdh2). Inhibition of TSP-1 from MEFs reverts abnormal migration (16,51). Cadherin 2 
(Cdh2) also known as N-cadherin (NCAD) inhibits Schwann cell migration (52). Cyclin 
D1a repressed RhoB. Emerging evidence points to a tumor-suppressive role for RhoB 
(53-55) which antagonizes Ras/PI3K/Akt-dependent transformation, apoptosis and 
metastasis in vivo (56). Stathmin, which was induced by cyclin D1a, promotes cell 
motility (34,57). Cde-12/Elmo1 is required for phagocytosis and cell migration (58). 
Thus, cyclin D1 downregulates the expression of TSP-1, Cdh2 and RhoB, which inhibit 
cell migration while upregulating the expression of Stathmin 1 and Elmo1, which are 
required for cell migration.  
 
The human cyclin D1 gene harbors a common polymorphism that has been 
associated with increased risk of cancer development. Compared with individuals of the 
A/G or G/G genotypes, those harboring the A/A genotype have an increased proclivity 
towards tumorigenesis and worse prognosis (18-20,22). The A allele is associated with 
synthesis of the cyclin D1b isoform (18). In cells, cyclin D1b has an increased 
transforming capacity (26). Our finding that p27KIP1 levels are reduced in cyclin D1b-
expressing cells and that p27
KIP1
 binds cyclin D1b relatively poorly offers one 
explanation for why production of this isoform might be associated with increased 
cancer risk, based on the improved ability of cyclin D1b to evade restraint by p27
KIP1 
as 
compared to cyclin D1a.   
 
The current studies demonstrated the importance of the cyclin D1a carboxyl 
terminus encoded by exon 5 in binding p27
KIP1
. Cyclin D1b or a carboxyl terminal 
deletion mutant of cyclin D1 (cyclin D1N2) either reduced or abolished interaction with 
p27
KIP1
 in mammalian 2-hybrid analysis (Fig. 5A-C). Consistent with our studies of 
p27
KIP1 
, previous studies of p21
CIP1
 assessed in  
S. Cerevisiae using a LexA-op-lacZ system, had shown that deletion of the C-terminal 
residues (267-295) reduced association with p21CIP1 (59). In addition, these prior 
studies demonstrated deletion of the cyclin D1a N-terminal 40 residues reduced 
interaction with p21
CIP1 
indicating the importance of both N and C-terminal interaction 
made between the cyclin D1 and the cdk inhibitor proteins.  
 
The role of p27
KIP1 
in cellular migration appears to vary with cell and tumor 
type. Therefore, the effect of cyclin D1a vs. cyclin D1b on migration may also vary by 
cell type. Reintroducing p27
KIP1 
into p27
KIP1-/-
 cells promotes migration by inhibition of 
Rho signaling (33). However, p27KIP1 inhibits cell migration in fibrosarcoma cells, where 
p27
KIP1 
binds to and inhibits the function of the microtubule destablizing protein stathmin 
(34). Binding of p27KIP1 to cyclins is important for inhibiting cyclin D/Cdk4 and cyclin 
E/Cdk2 kinase activity and p27
KIP1 
has an important role as a tumor suppressor. 
Reduction in p27
KIP1
 levels correlates with tumor aggressiveness. For example, p27
KIP1 
deficiency accelerates cancer formation caused by mutation of the Apc or 
Neu/ErbB2/HER2 genes (39). Moreover, mice lacking even a single copy of p27KIP1 
have an increased susceptibility to carcinogenesis (60-62), illustrating the importance of 
its abundance in tumor suppression. Thus, reduction in p27
KIP1 
binding by cyclin D1b 
may impact tumor suppressor activity, perhaps in a cell type-specific manner.   
 We found that cyclin D1a but not cyclin D1b restored defective cellular 
migration of cyclin D1
-/-
 MEFs. Previous studies have demonstrated a role for p27
KIP1
 
in promoting cellular migration through binding to RhoA which regulates cytoskeletal 
structure, cell adhesion, and cellular migration (33). Cyclin D1a induction of migration 
is dependent on p27
KIP1 (17). Our finding of a reduced p27KIP1 binding capacity for 
cyclin D1b suggests that its poor pro-migratory activity reflects a defect in p27
 KIP1
-
dependent migration. Thus, by evading restraint by p27
KIP1
, cyclin D1b may favor cell 
cycle deregulation at the cost of reduced migratory capability. Further in vivo studies 
may be useful to distinguish how differential expression of the cyclin D1a and D1b 
isoforms may impact cancer development and progression at distinct levels.  
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Figures 
 
Figure 1. Cyclin D1a and cyclin D1b regulate overlapping and distinct gene 
expression profiles. (A). Transcriptional activity of PPARγ, NRF1, and AR assayed in 
HEK 293T cells. Cells were transfected with expression vectors for Gal4-AR, Gal4-
PPARγ or Gal4-NRF1 along with either 3xFLAG vector, 3x FLAG cyclin D1a, or 3x 
FLAG cyclin D1b constructs and the reporter, pG5-LUC. The data represents triplicate 
experiments and relative luciferase units based on the mean data normalized to basal 
activity plus standard error of the mean (SEM). (B). Comparison of cyclin D1-regulated 
genes determined by microarray analysis (For full details the GEO accession number 
obtained is GSE9161 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zfellwagiuaagfa&acc=GSE9161).  
Comparison is shown between cyclin D1
-/-
3T3 cells transduced with expression vectors 
encoding cyclin D1a, cyclin D1b or control vector.   
 
  
Figure 2. Cyclin D1a but not cyclin D1b enhances cellular migration. (A). Confocal 
microscopy of cyclin D1
-/-
MEFs transduced with cyclin D1a or cyclin D1b retrovirus. (left 
panel) F-actin staining and (right panel) paxillin (green), tyrosine phosphorylated paxillin 
(Y118) (red) and DAPI (blue). Cyclin D1-/-MEFs were transduced with retroviral 
expression plasmids encoding either the cyclin D1a or cyclin D1b isoform. The GFP 
expressing cells were sorted by FACS and were then examined by confocal 
microscopy. (B). Cellular velocity is shown as mean ± SEM. (C). Western blot analysis 
of cyclin D1
-/-
MEFs transduced with retroviral expression vectors cyclin D1a or cyclin 
D1b. Antibodies were directed  
Downloaded from  www.jbc.org  at Thomas Jefferson University on February 5, 2008  
to FLAG (M2), p27KIP1, phospho-cofilin (Ser3) (as a marker of activated Rho signaling), 
and β-tubulin and vinculin as total protein loading controls.  
 
 
  
 
 
 
 
Figure 3. Cyclin D1a but not cyclin D1b increases the abundance of p27
KIP1
 
protein. (A). Cyclin D1-/-MEFs were transduced with retroviral vectors for cyclin D1a or 
cyclin D1b and subjected to Western blot analysis. A number was assigned for each 
separate batch of MEFs generated and is indicated above each Western blot. (B). 
Northern analysis for p27
KIP1
 (C). QT-PCR for p27KIP1. Data are shown as mean ± SEM 
(n=4).  
 
  
 
 
 
 
 
Figure 4. Cyclin D1a increases p27
KIP1
 protein stability. (A,B) Measurement of 
p27
KIP1
 protein degradation after inhibition of protein synthesis with cycloheximide 
(CHX). Proliferating MEFs were transduced with the retroviral vectors as indicated and 
were treated with 10 µg/ml cycloheximide for the indicated times. p27
KIP1 
levels were 
measured by Western blot shown as representative example. P27
KIP1 
levels were 
normalized to β-tubulin as a protein loading control and densitometric analysis of 
representative Western blot studies (B). (C) Pulse chase analysis for p27KIP1 
abundance. A representative example is shown. The data are mean from densitometry 
of n=3 separate experiments.   
 
  
 
 
 
Figure 5. Cyclin D1b is defective in p27
KIP1
-binding. (A). Schematic representation of 
cyclin D1 constructs used in (B, D) mammalian two hybrid. The cyclin D1 cDNAs shown 
in (A) were linked to either the VP16 (left panel) transactivation domain or Gal4 (right 
panel) DNA binding domin. p27KIP1 was linked to the cognate mammalian 2-hybrid 
interaction domain. The interaction is shown as relative luciferase activity for N>5 
separate transfections as mean ± SEM. (C). Cyclin D1-/-MEFs transduced with retroviral 
vectors for cyclin D1a or cyclin D1b were analyzed by Western blot (left hand panel) or 
immunoprecipitation – Western blot. Cyclin D1 immunoprecipitation was conducted with 
the FLAG antibody with subsequent Western blot for cyclin D1 (DCS-6) or p27KIP1 (C-
19). (D). Interaction of cyclin D1 constructs with Cdk4 in mammalian 2-hybrid. The data 
is shown throughout as mean ± SEM for N> 5 separate experiments.   
 
 
 
 
  
